|
Regulations &
Codified CSA > CFR >
Section 1308 > Section 1308.13
Section 1308.13 Schedule III.
(a) Schedule III shall consist of the drugs and other substances, by whatever official name,
common or usual name, chemical name, or brand name designated, listed in this section. Each
drug or substance has been assigned the DEA Controlled Substances Code Number set forth
opposite it.
(b) Stimulants. Unless specifically excepted or unless listed in another schedule, any material,
compound, mixture, or preparation which contains any quantity of the following substances
having a stimulant effect on the central nervous sxstem, including its salts, isomers (whether
optical, position, or geometric), and salts of such isomers whenever the existence of such salts,
isomers, and salts of isomers is possible within the specific chemical designation:
| (1) Those
compounds, mixtures, or preparations in dosage unit form containing any
stimulant substances listed in schedule II which compounds, mixtures, or
preparations were listed on August 25, 1971, as excepted compounds under
Sec. 1308.32,
and any other drug of the quantitative composition shown in that list
for those drugs or which is the same except that it contains a lesser
quantity of controlled substances
|
1405
|
| (2)
Benzphetamine
|
1228
|
| (3)
Chlorphentermine
|
1645
|
| (4)
Clortermine
|
1647
|
| (5)
Phendimetrazine
|
1615
|
(c) Depressants. Unless specifically excepted or unless listed in another schedule, any material,
compound, mixture, or preparation which contains any quantity of the following substances
having a depressant effect on the central nervous system:
(1)
Any compound, mixture or preparation containing:
| (i) Amobarbital
|
2126
|
| (ii) Secobarbital |
2316
|
| (iii) Pentobarbital |
2271
|
or any salt thereof and one or more other active medicinal ingredients which
are not listed in any schedule. |
(2) Any
suppository dosage form containing:
| (i)
Amobarbital |
2126
|
| (ii)
Secobarbital |
2316
|
| (iii)
Pentobarbital |
2271
|
or
any salt of any of these drugs and approved by the Food and Drug
Administration for marketing only as a suppository.
|
| (3) Any
substance which contains any quantity of a derivative of barbituric acid
or any salt thereof
|
2100
|
| (4)
Chlorhexadol
|
2510
|
| (5) Embutramide
|
2020
|
| (6) Any drug
product containing gamma hydroxybutyric acid, including its salts,
isomers, and salts of isomers, for which an application is approved
under section 505 of the Federal Food, Drug, and Cosmetic Act |
2012 |
| (7)
Ketamine,
its salts, isomers, and salts of isomers |
7285 |
| [Some
other names for ketamine: (+)-2-(2-chlorophenyl)-2-(methylamino)-cyclohexanone] |
| (8) Lysergic
acid
|
7300
|
| (9) Lysergic
acid amide
|
7310
|
| (10) Methyprylon
|
2575
|
| (12) Sulfondiethylmethane
|
2600
|
| (13) Sulfonethylmethane
|
2605
|
| (13) Sulfonmethane
|
2610
|
| (14) Tiletamine and zolazepam or any salt thereof
|
7295
|
Some
trade or other names for a tiletamine-zolazepam combination product:
Telazol
Some trade or other names for tiletamine:
2-(ethylamino)-2-(2-thienyl)-cyclohexanone
Some trade or other names for zolazepam:
4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo-[3,4-e]
[1,4]-diazepin-7(1H)-one, flupyrazapon
|
(d) Nalorphine 9400.
(e) Narcotic Drugs. Unless specifically excepted or unless listed in another
schedule:
(1) Any
material, compound, mixture, or preparation containing any of the following narcotic drugs, or
their salts calculated as the free anhydrous base or alkaloid, in limited quantities as set forth
below:
| (i)
Not
more than 1.8 grams of codeine per 100 milliliters or not more than 90
milligrams per dosage unit, with an equal or greater quantity of an
isoquinoline alkaloid of opium
|
9803
|
| (ii)
Not
more than 1.8 grams of codeine per 100 milliliters or not more than 90
milligrams per dosage unit, with one or more active, nonnarcotic
ingredients in recognized therapeutic amounts |
9804
|
| (iii)
Not
more than 300 milligrams of dihydrocodeinone (hydrocodone) per 100
milliliters or not more than 15 milligrams per dosage unit, with a
fourfold or greater quantity of an isoquinoline alkaloid of opium |
9805
|
| (iv)
Not
more than 300 milligrams of dihydrocodeinone (hydrocodone) per 100
milliliters or not more than 15 milligrams per dosage unit, with one or
more active nonnarcotic ingredients in recognized therapeutic amounts |
9806
|
| (v)
Not
more than 1.8 grams of dihydrocodeine per 100 milliliters or not more
than 90 milligrams per dosage unit, with one or more active nonnarcotic
ingredients in recognized therapeutic amounts
|
9807
|
| (vi)
Not
more than 300 milligrams of ethylmorphine per 100 milliliters or not
more than 15 milligrams per dosage unit, with one or more active,
nonnarcotic ingredients in recognized therapeutic amounts
|
9808
|
| (vii)
Not
more than 500 milligrams of opium per 100 milliliters or per 100 grams
or not more than 25 milligrams per dosage unit, with one or more active,
nonnarcotic ingredients in recognized therapeutic amounts |
9809
|
| (viii) Not
more than 50 milligrams of morphine per 100 milliliters or per 100
grams, with one or more active, nonnarcotic ingredients in recognized
therapeutic amounts |
9810
|
(2) Any material,
compound, mixture, or preparation containing any of the following narcotic drugs
or their salts, as set forth below:
(i)
Buprenorphine
(ii) [Reserved] |
9064 |
(f) Anabolic Steroids. Unless specifically excepted or unless listed in
another schedule, any material, compound, mixture or preparation containing any
quantity of the following substances, including its salts, esters and ethers:
|
(1) Anabolic steroids (see Sec. 1300.01 of this chapter)
|
4000
|
| (2) [Reserved]
|
|
(g) Hallucinogenic substances.
| (1)
Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin
capsule in a U.S. Food and Drug Administration approved product |
7369 |
| [Some
other names for dronabinol: (6aR-trans)-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo
[b,d]pyran-1-ol] or (-)-delta-9-(trans)-tetrahydrocannabinol] |
[39 FR 22142, June 20, 1974, as amended at 41 FR 43401, Oct. 1, 1976; 43 FR 3359, Jan. 25,
1978; 44 FR 40888, July 13, l979; 46 FR 52334, Oct. 27, 1981; 51 FR 5320, Feb.
13, 1986; 52 FR 2222, Jan. 21, 1987; 52 FR 5952, Feb. 27, 1987; 56 FR 5754, Feb.
13, 1991; 56 FR 11932, Mar. 21, 1991; 62 FR 13968, Mar. 24, 1997; 64 FR 35930,
July 2, 1999; 64 FR 37675, July 13, 1999; 65 FR 13238 Mar. 13, 2000; 65 FR
17440, Apr. 3, 2000; 67 FR 62370, Oct. 7, 2002 ;
70 FR 74657, Dec. 16, 2005; 71 FR 51116, Aug 29, 2006]
Back to Top
NOTICE: This is an
unofficial version. An official version of this publication may be obtained
directly from the Government Printing Office (GPO).
|
